Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:49 UTC |
---|
HMDB ID | HMDB0015010 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Conivaptan |
---|
Description | Conivaptan is only found in individuals that have used or taken this drug. It is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).Conivaptan is a dual AVP antagonist with nanomolar affinity for human arginine vasopressin V1A and V2 receptors in vitro. This antagonism occurs in the renal collecting ducts, resulting in aquaresis, or excretion of free water. |
---|
Structure | CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1 InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37) |
---|
Synonyms | Value | Source |
---|
4'-((4,5-Dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide | ChEBI | YM 087 | HMDB | YM-087 | HMDB | Conivaptan hydrochloride | HMDB | Vaprisol | HMDB | (1,1'-Biphenyl)-2-carboxamide, N-(4-((4,5-dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)phenyl)-, monohydrochloride | HMDB | 4''-((4,5-Dihydro-2-methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide | HMDB |
|
---|
Chemical Formula | C32H26N4O2 |
---|
Average Molecular Weight | 498.5744 |
---|
Monoisotopic Molecular Weight | 498.205576096 |
---|
IUPAC Name | N-(4-{4-methyl-3,5,9-triazatricyclo[8.4.0.0²,⁶]tetradeca-1(14),2(6),3,10,12-pentaene-9-carbonyl}phenyl)-2-phenylbenzamide |
---|
Traditional Name | vaprisol |
---|
CAS Registry Number | 210101-16-9 |
---|
SMILES | CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1 |
---|
InChI Identifier | InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37) |
---|
InChI Key | IKENVDNFQMCRTR-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Anilides |
---|
Direct Parent | Benzanilides |
---|
Alternative Parents | |
---|
Substituents | - Benzanilide
- Biphenyl
- Benzazepine
- Benzamide
- Benzoic acid or derivatives
- Benzoyl
- Azepine
- Azole
- Heteroaromatic compound
- Imidazole
- Tertiary carboxylic acid amide
- Carboxamide group
- Secondary carboxylic acid amide
- Carboxylic acid derivative
- Organoheterocyclic compound
- Azacycle
- Organooxygen compound
- Organonitrogen compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.0018 g/L | Not Available | LogP | 6.3 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Conivaptan,1TMS,isomer #1 | CC1=NC2=C(CCN(C(=O)C3=CC=C(N(C(=O)C4=CC=CC=C4C4=CC=CC=C4)[Si](C)(C)C)C=C3)C3=CC=CC=C32)[NH]1 | 4646.7 | Semi standard non polar | 33892256 | Conivaptan,1TMS,isomer #1 | CC1=NC2=C(CCN(C(=O)C3=CC=C(N(C(=O)C4=CC=CC=C4C4=CC=CC=C4)[Si](C)(C)C)C=C3)C3=CC=CC=C32)[NH]1 | 4348.3 | Standard non polar | 33892256 | Conivaptan,1TMS,isomer #1 | CC1=NC2=C(CCN(C(=O)C3=CC=C(N(C(=O)C4=CC=CC=C4C4=CC=CC=C4)[Si](C)(C)C)C=C3)C3=CC=CC=C32)[NH]1 | 5941.0 | Standard polar | 33892256 | Conivaptan,1TMS,isomer #2 | CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C32)N1[Si](C)(C)C | 4805.9 | Semi standard non polar | 33892256 | Conivaptan,1TMS,isomer #2 | CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C32)N1[Si](C)(C)C | 4478.6 | Standard non polar | 33892256 | Conivaptan,1TMS,isomer #2 | CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C32)N1[Si](C)(C)C | 6010.3 | Standard polar | 33892256 | Conivaptan,2TMS,isomer #1 | CC1=NC2=C(CCN(C(=O)C3=CC=C(N(C(=O)C4=CC=CC=C4C4=CC=CC=C4)[Si](C)(C)C)C=C3)C3=CC=CC=C32)N1[Si](C)(C)C | 4602.3 | Semi standard non polar | 33892256 | Conivaptan,2TMS,isomer #1 | CC1=NC2=C(CCN(C(=O)C3=CC=C(N(C(=O)C4=CC=CC=C4C4=CC=CC=C4)[Si](C)(C)C)C=C3)C3=CC=CC=C32)N1[Si](C)(C)C | 4355.4 | Standard non polar | 33892256 | Conivaptan,2TMS,isomer #1 | CC1=NC2=C(CCN(C(=O)C3=CC=C(N(C(=O)C4=CC=CC=C4C4=CC=CC=C4)[Si](C)(C)C)C=C3)C3=CC=CC=C32)N1[Si](C)(C)C | 5540.2 | Standard polar | 33892256 | Conivaptan,1TBDMS,isomer #1 | CC1=NC2=C(CCN(C(=O)C3=CC=C(N(C(=O)C4=CC=CC=C4C4=CC=CC=C4)[Si](C)(C)C(C)(C)C)C=C3)C3=CC=CC=C32)[NH]1 | 4870.1 | Semi standard non polar | 33892256 | Conivaptan,1TBDMS,isomer #1 | CC1=NC2=C(CCN(C(=O)C3=CC=C(N(C(=O)C4=CC=CC=C4C4=CC=CC=C4)[Si](C)(C)C(C)(C)C)C=C3)C3=CC=CC=C32)[NH]1 | 4559.0 | Standard non polar | 33892256 | Conivaptan,1TBDMS,isomer #1 | CC1=NC2=C(CCN(C(=O)C3=CC=C(N(C(=O)C4=CC=CC=C4C4=CC=CC=C4)[Si](C)(C)C(C)(C)C)C=C3)C3=CC=CC=C32)[NH]1 | 5897.6 | Standard polar | 33892256 | Conivaptan,1TBDMS,isomer #2 | CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C32)N1[Si](C)(C)C(C)(C)C | 5009.0 | Semi standard non polar | 33892256 | Conivaptan,1TBDMS,isomer #2 | CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C32)N1[Si](C)(C)C(C)(C)C | 4704.1 | Standard non polar | 33892256 | Conivaptan,1TBDMS,isomer #2 | CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C32)N1[Si](C)(C)C(C)(C)C | 5939.3 | Standard polar | 33892256 | Conivaptan,2TBDMS,isomer #1 | CC1=NC2=C(CCN(C(=O)C3=CC=C(N(C(=O)C4=CC=CC=C4C4=CC=CC=C4)[Si](C)(C)C(C)(C)C)C=C3)C3=CC=CC=C32)N1[Si](C)(C)C(C)(C)C | 4962.4 | Semi standard non polar | 33892256 | Conivaptan,2TBDMS,isomer #1 | CC1=NC2=C(CCN(C(=O)C3=CC=C(N(C(=O)C4=CC=CC=C4C4=CC=CC=C4)[Si](C)(C)C(C)(C)C)C=C3)C3=CC=CC=C32)N1[Si](C)(C)C(C)(C)C | 4819.6 | Standard non polar | 33892256 | Conivaptan,2TBDMS,isomer #1 | CC1=NC2=C(CCN(C(=O)C3=CC=C(N(C(=O)C4=CC=CC=C4C4=CC=CC=C4)[Si](C)(C)C(C)(C)C)C=C3)C3=CC=CC=C32)N1[Si](C)(C)C(C)(C)C | 5506.7 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Conivaptan GC-MS (Non-derivatized) - 70eV, Positive | splash10-001i-0902300000-bbe0e959903728fcb9dd | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Conivaptan GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Conivaptan GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Conivaptan 10V, Positive-QTOF | splash10-0002-0302900000-6919f937d99ae30f7649 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Conivaptan 20V, Positive-QTOF | splash10-0f89-0904200000-e75a97ac740c34bf49c5 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Conivaptan 40V, Positive-QTOF | splash10-001i-1900000000-6f55bb7a14d7800ba3bf | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Conivaptan 10V, Negative-QTOF | splash10-0002-0100900000-0f42736a94ca90444bd4 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Conivaptan 20V, Negative-QTOF | splash10-0002-0633900000-0ddde7ac59a20f36c648 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Conivaptan 40V, Negative-QTOF | splash10-0f7p-4910000000-980164b1ab5bb53b62c3 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Conivaptan 10V, Positive-QTOF | splash10-0002-0101900000-c1f2e78661c9808fefca | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Conivaptan 20V, Positive-QTOF | splash10-001j-0901500000-5f41dd77313e65019943 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Conivaptan 40V, Positive-QTOF | splash10-0f89-0900000000-4bb1a973f98966b35a7f | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Conivaptan 10V, Negative-QTOF | splash10-0002-0011900000-6e04a9e57ffbe150e669 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Conivaptan 20V, Negative-QTOF | splash10-0v4j-1922700000-83b2b29e14f1d1ecda1b | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Conivaptan 40V, Negative-QTOF | splash10-0v4l-1820900000-af313b1f204951185982 | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|
General References | - Ali F, Raufi MA, Washington B, Ghali JK: Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. [PubMed:17919259 ]
- Mao ZL, Stalker D, Keirns J: Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin Ther. 2009 Jul;31(7):1542-50. doi: 10.1016/j.clinthera.2009.07.011. [PubMed:19695403 ]
- Ghali JK, Farah JO, Daifallah S, Zabalawi HA, Zmily HD: Conivaptan and its role in the treatment of hyponatremia. Drug Des Devel Ther. 2009 Dec 29;3:253-68. [PubMed:20054444 ]
|
---|